Type 2 Diabetes

A systematic review and meta-analysis of a dozen trials assessing the MiniMed 670G system provides insight into the effects of the hybrid closed-loop system on A1c and time in range among patients with type 1 diabetes.

A 23-year study suggests presence of autoantibodies could aid clinicians in predicting the risk of developing type 1 diabetes among women with gestational diabetes.

Analysis of the UK Biobank cohort details a graded increase in risk of cardiovascular and renal events across the glycemic spectrum, including among patients with prediabetes.

Analysis of data from the FIDELIO-DKD trial suggests use of finerenone was associated with a nearly 30% reduction in new-onset atrial fibrillation among patients within the phase 3 trial.

An analysis of 9 trials examining SGLT2 inhibitors in patients with heart failure provides insight into the effects of the agents across the spectrum of heart failure, including those with decreased eGFR and preserved ejection fraction.

An analysis of FIDELIO-DKD indicates use of finerenone was associated with significant reductions in risk of new-onset atrial fibrillation in patients with type 2 diabetes and chronic kidney disease.

While the trial failed to meet its primary endpoint, results of DARE-19 provide valuable insight into the effects of SGLT2 inhibition and use of dapagliflozin in patients with COVID-19.

An ACC.21 study assessing the risk of adverse cardiovascular and renal outcomes found a graded increase in risk across the entire glycemic spectrum, including prediabetic levels.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Research from ARVO 2021 details the complexities and current challenges faced when attempting to address the burden of diabetic eye disease while the number of patients with diabetes in the US continues to balloon.

A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.

An analysis of nearly 2 million patients suggests an increased BMI around the age of 18 was linked to a graded increase in the risk of ischemic stroke in midlife, regardless of diabetes status.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

An analysis of data from more than 250k kidney transplant patients details the increased risk of mortality and graft failure according to diabetes status among these patients.

Bigfoot Medical announced the FDA granted 510(k) clearance to the Bigfoot Unity System for use in patients with type 1 or type 2 diabetes aged 12 years and older.

The smart pen cap system is associated with real-time hypoglycemia alerts and insulin dose recommendations.

An analysis presented ahead of ACC.21 details the increased risk of MACE associated with prediabetes, suggesting patients were at nearly twice the risk of experiencing a major cardiovascular event.

A systematic review and meta-analysis of studies examining pediatric type 2 diabetes indicate hypertension or albuminuria was present among approximately 20% of children with type 2 diabetes.

An analysis from ACC.21 is providing an overview of the impact of prediabetes compared to normoglycemia on risk for major adverse cardiovascular disease events.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.

A study from APA 2021 suggests type 1 diabetes mellitus in adolescence was linked to increased probability of attention deficit hyperactivity disorder.

A new study finds the top 10 future research priorities into diabetes and pregnancy.

An analysis of claims data from more than 7k patients suggests patients with severe obesity and type 2 diabetes who underwent bariatric surgery experienced a 68% reduction in cardiac mortality and 34% reduction in cardiac events compared against standard medical management.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.